WS
IONS icon

Wedbush Securities’s Ionis Pharmaceuticals IONS Stock Holding History

Wedbush Securities’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,640
Closed -$214K – 1012
2019
Q1 		$214K Buy
+2,640
New +$170K 0.02% 746

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wedbush Securities's IONS Position: Q2 2019 in Review

Wedbush Securities sold out of Ionis Pharmaceuticals (IONS) in Q2 2019, closing a stake of 2,640 shares — an estimated $214K sold.

Wedbush Securities first reported a position in IONS in Q1 2019 and held it in 1 quarter. The position peaked at $214K in Q1 2019. 396 funds tracked by Wall St. Rank hold IONS as of Q2 2019.

  • Wedbush Securities reported no remaining Ionis Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Wedbush Securities sold 2,640 Ionis Pharmaceuticals shares in Q2 2019, an estimated $214K.
  • Wedbush Securities first reported a position in Ionis Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Wedbush Securities's Ionis Pharmaceuticals position peaked at $214K in Q1 2019.
  • 396 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2019.

Based on Wedbush Securities's 13F filing for Q2 2019, filed 1 Aug 2019.